Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1

Melissa Cudmore, Shakil Ahmad, Bahjat Al-Ani, Takeshi Fujisawa, Heather Coxall, Kunal Chudasama, Luke R Devey, Stephen J Wigmore, Allyah Abbas, Peter W Hewett, Asif Ahmed

Research output: Contribution to journalArticlepeer-review

Abstract

Preeclampsia is characterized clinically by hypertension and proteinuria. Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 [VEGFR-1]) and soluble endoglin (sEng) are elevated in preeclampsia, and their administration to pregnant rats elicits preeclampsia-like symptoms. Heme oxygenase-1 (HO-1) and its metabolite carbon monoxide (CO) exert protective effects against oxidative stimuli. Thus, we hypothesized that HO-1 upregulation may offer protection against preeclampsia by inhibiting sFlt-1 and sEng release.
Original languageEnglish
Pages (from-to)1789-97
Number of pages9
JournalCirculation
Volume115
Issue number13
DOIs
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1'. Together they form a unique fingerprint.

Cite this